Cellectis
Created in 1999
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
4,549 43,278Activities
Technologies
Entity types
Location
8 Rue de la Croix Jarry, 75013 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 232
SIREN
428859052Engaged corporates
19
6 8Added in Motherbase
5 years, 4 months ago
deeptech Value proposition
Cellectis is developing life-changing product candidates to target and eradicate cancer cells.
Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.
Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic, and off-the-shef CART therapiesOriginal language
Cellectis is developing life-changing product candidates to target and eradicate cancer cells.
Cellectis is a global clinical-stage biopharmaceutical company. Pioneers and innovators in our field, our mission is to develop innovative treatments for patients with unmet medical needs.
With 25 years of expertise, we have the best-in-class gene editing platform focusing on immuno-oncology, and gene therapy. Through our efficient and precise TALEN® technology, we create allogeneic CAR-T cells capable of recognizing and combating cancer cells.
Today, our two* clinical programs target patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
We are fully integrated and a leader in end-to-end gene editing, allogeneic CAR T-cell companies. With our in-house manufacturing, we control our gene and cell therapy process from start to finish with starting materials produced in Paris (France) and CAR-T therapy products created in Raleigh, NC (USA).
We also have several ongoing strong collaborations, based on our TALEN® technology, with leading cell & gene therapy companies, including our recent partnership with AstraZeneca, to develop new product candidates in oncology, immunology, and treatment of rare diseases.
At Cellectis, we are committed to a cure.
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
To find out more about us, visit our website: www.cellectis.com. To learn more about our community guidelines, visit: http://www.cellectis.com/en/social-media-guidelines/
Follow our other social media accounts: @cellectis on LinkedIn on X (formerly Twitter) .
(*) On November 4, 2024, Cellectis decided to focus its current development efforts on the BALLI-01 and NATHALI-01 studies and therefore to deprioritize the development of UCART123.
TALEN® is a registered trademark owned by the Cellectis Group.
Home | Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer
https://www.cellectis.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Event 1 Jun 2020 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 2 Nov 2016 | | |
 Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Bayer Pharmaceutical, Chemistry, Chemical Manufacturing | Not capitalistic Partnership Not event 30 Jan 2014 | | |
 BFM Business Media, Broadcast Media Production and Distribution | BFM Business Media, Broadcast Media Production and Distribution | Other 6 Apr 2021 9 May 2024 | | |
 Moderna Pharmaceutical, Biotechnology, Biotechnology Research | Moderna Pharmaceutical, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 15 Jan 2021 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 11 May 2021 24 Apr 2023 | | |
 HEC Paris Higher Education | HEC Paris Higher Education | Not capitalistic Partnership Not event 10 Dec 2020 18 Sep 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Not capitalistic Not partnership Event 5 Oct 2021 | | |
 L'Express Media, Newspaper Publishing | L'Express Media, Newspaper Publishing | Not capitalistic Not partnership Event 4 Nov 2021 27 Nov 2023 | | |